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Abstract 
Accumulation of amyloid-β (Aβ) in plaques in the brain and in artery walls as 
cerebral amyloid angiopathy indicates a failure of elimination of Aβ from the brain with age 
and Alzheimer's disease. A major pathway for elimination of Aβ and other soluble 
metabolites from the brain is along basement membranes within the walls of cerebral arteries 
that represent the lymphatic drainage pathways for the brain. The motive force for the 
elimination of Aβ along this perivascular pathway appears to be the contrary (reflection) 
wave that follows the arterial pulse wave. Following injection into brain parenchyma, Aβ 
rapidly drains out of the brain along basement membranes in the walls of cerebral arteries; 
such drainage is impaired in apolipoprotein E ε4 (ApoE4) mice. For drainage of Aβ to occur 
in a direction contrary to the pulse wave some form of attachment to basement membrane 
would be required to prevent reflux of Aβ back into the brain during the passage of the 
subsequent pulse wave. In this study, we show first that apolipoprotein E co-localizes with 
Aβ in basement membrane drainage pathways in the walls of arteries. Secondly, we show by 
Atomic Force Microscopy that attachment of ApoE4/Aβ complexes to basement membrane 
laminin is significantly weaker than ApoE3/Aβ complexes. These results suggest that 
perivascular elimination of ApoE4/Aβ complexes would be less efficient than with other 
isoforms of apolipoprotein E, thus endowing a higher risk for Alzheimer's disease. 
Therapeutic correction for ApoE4/Aβ/laminin interactions may increase the efficiency of 
elimination of Aβ in the prevention of Alzheimer's disease. 
 
Keywords: Apolipoprotein E, perivascular clearance pathways, laminin, atomic force 
microscopy, amyloid-β. Cerebral amyloid angiopathy, Alzheimer's disease 
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1. Introduction 
A key feature of Alzheimer's disease pathology is the extracellular accumulation of 
soluble amyloid-β (Aβ) and of insoluble Aβ as plaques in brain parenchyma and in the walls 
of cerebral arteries as cerebral amyloid angiopathy (CAA) [1, 2]. These features indicate that 
there is a failure of elimination of Aβ from the brain with increasing age and in Alzheimer's 
disease [3]. Mechanisms for elimination of Aβ from the brain include enzymatic degradation 
by neprilysin within brain tissue and artery walls; absorption of Aβ into the blood mediated 
by low density lipoprotein receptor-1 and elimination by lymphatic drainage along basement 
membranes in the walls of cerebral capillaries and arteries [4]. Accumulation of insoluble 
fibrillar Aβ in the walls of capillaries and arteries in CAA reflects failure of elimination of 
Aβ along lymphatic drainage pathways with age and Alzheimer's disease [5]. 
When soluble tracers, including Aβ, are injected into the brain parenchyma, they are 
rapidly eliminated along basement membranes of capillaries towards cervical lymph nodes 
[6, 7]. The pattern of deposition of Aβ in the walls of capillaries and arteries in human CAA 
exactly mirrors the lymphatic drainage pathways defined in experimental tracer studies [5]. 
Tracers and Aβ appear to leave the walls of the carotid artery in the neck at the level of 
cervical lymph nodes as they drain from the brain to regional lymph nodes in the neck [6, 8]. 
Perivascular drainage of Aβ from the brain is impaired with age as shown experimentally and 
by the presence of CAA in aging humans [9]. Aβ secreted by amyloid precursor protein 
(APP)-transgenic mice harboring the Swedish double mutation driven by a neuron specific 
promoter is observed in the perivascular drainage pathways as CAA co-localized with 
apolipoprotein E (ApoE) [1]. Furthermore, perivascular drainage of Aβ is impaired in mice 
expressing human apolipoprotein E ε4 (ApoE4) suggesting that the risk factor for 
Alzheimer's disease in patients possessing the ε4 allele of ApoE may be related to a failure of 
elimination of Aβ from brain [10]. 
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Studies on the motive force for perivascular drainage of Aβ from the brain suggest 
that solutes are driven along basement membranes in the walls of arteries by the contrary 
(reflection) wave that follows the pulse wave [11]. In order for this mechanism to function 
effectively, some form of attachment of transported material to basement membrane proteins 
would be required in order to prevent reflux of material during passage of the pulse wave 
itself. If no attachment activity were present, Aβ and other solutes would oscillate within the 
basement membrane rather than be driven rapidly out of the brain as has been observed 
experimentally. One of the major candidates for performing such attachment activity for Aβ 
is ApoE. 
ApoE is the predominant lipoprotein in the brain and regulates transport of cholesterol 
from astrocytes to neurons [12-14]. Three APOE alleles (ε2, ε3 and ε4) encode the production 
of corresponding protein isoforms (E2, E3 and E4).  Binding of Aβ to ApoE has been 
proposed as a mechanism by which Aβ is transported across the blood-brain barrier [4] and 
levels of ApoE are lower in ApoE4-positive individuals than in ApoE3 carriers [15]. Recent 
work has demonstrated minimal direct physical interaction between ApoE and soluble Aβ 
within the cerebrospinal fluid [16]. Thus, the role of ApoE in mediating the clearance of Aβ 
from the brain remains unresolved.  
Since Aβ40 is the predominant type of Aβ found in CAA [17], in the present study we 
tested the hypothesis that interactions of Aβ40 with protein components of cerebral vascular 
basement membranes, such as laminin, are stronger in the presence of ApoE3 than in the 
presence of apoE4. If this hypothesis is substantiated, it would suggest that perivascular 
drainage of Aβ in individuals possessing ApoE4 would be less efficient due to defective 
attachment of Aβ/ApoE4 complexes to basement membranes during perivascular lymphatic 
drainage. This would ultimately lead to failure of elimination of Aβ from the brain and its 
deposition in artery walls as CAA. .  
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In order to test the hypothesis, we first identified the location of ApoE in relation to 
fibrillary Aβ within basement membranes in the walls of arteries in AD. Secondly, we 
performed single-molecule force spectroscopy with an atomic force microscope (AFM) in 
order to determine the force of attachment between Aβ/ApoE4 complexes and the basement 
membrane protein, laminin. We then compared the attachment forces of Aβ/ApoE4 
complexes with those of Aβ/ApoE3.  
 
2. Materials and Methods 
2.1 Materials for AFM tip functionalization 
Analytical grade materials used for AFM tip functionalization were obtained from 
Sigma Aldrich, UK. The following chemicals were used: ethanol, chloroform, ethanolamine 
hydrochloride (ethanolamine-HCl), dimethylsulfoxide (DMSO), triethylamine (TEA), 
sodium hydroxide (NaOH), sodium cyanoborohydride (NaCNBH3). Aldehyde-PEG-NHS 
linker was purchased from Institute of Biophysics, University of Linz, Austria. Human 
recombinant laminin-511 was purchased from (BioLamina, Sweden), while human Aβ40 
(referred to as Aβ for the rest of the manuscript), human ApoE3 and human ApoE4 were 
from Cambridge Bioscience (Cambridge, UK). 
 
2.2 Immunofluorescence of human tissue 
Paraffin sections from 5 cases diagnosed with Alzheimer’s disease from the South 
West Dementia Brain Bank, Frenchay Hospital, Bristol were utilised for immunostaining. 
Sections of middle frontal gyrus were immunostained with antibodies specific for Aβ42 
(clone 21F12, 1:4000), pan-apolipoprotein E (pan-apoE, clone 5F6, 1:2000) provided by Elan 
Pharmaceuticals Inc. (USA).  We could not access an antibody specific for Aβ40 that worked 
on human tissue, so we used Aβ42, as we know that Aβ42 becomes entrapped in the 
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cerebrovascular amyloid deposits [18, 19].  Smooth muscle actin (SMA: clone 1A4, Dako, 
UK, 1:100) was used to identify smooth muscle cells in the blood vessel walls. 
Immunostaining was performed using the appropriate antigen retrieval methods for 
each primary antibody.  For Aβ42, pan-apoE and ApoE E4 sections were pre-treated with 
neat formic acid.  Triple immunostaining was detected using AF594 (red, Aβ42) or AF633 
(blue, pan-apoE) fluorochromes conjugated with biotinylated secondary antibodies (Life 
Technologies, UK) and SMA-FITC (Abcam, UK, 1:200, green), respectively. A Leica SP5 
confocal scanning microscope was used for imaging. 
 
2.3 Atomic force microscope measurements 
2.3.1 Functionalization of AFM measuring tips 
The AFM silicon nitride tips (MSNL-10, Bruker, UK) were functionalized with the 
desired protein following three modification steps: (1) amino functionalization, (2) 
modification with aldehyde-PEG-NHS linker, and (3) ligand coupling. AFM cantilevers were 
washed in chloroform three times and dried under a stream of nitrogen before tips were 
subjected to modification. Amino functionalization was done by esterification with 
ethanolamine at room temperature [20]. AFM tips were then placed in a closed container with 
the ethanolamine-HCl solution, left overnight, washed three times in DMSO and ethanol and 
dried under a stream of nitrogen. Subsequent functionalization steps were performed 
following a custom tip modification protocol provided by Agilent Technologies, Inc. [21]. 
The PEG linker was immobilized on aminated AFM probes by the NHS ester terminus (step 
2). 3.3 mg of aldehyde-PEG-NHS linker was dissolved in 1 ml chloroform, and transferred 
into a small glass reaction chamber. 10 l of thriethylamine was added before amino-
functionalized AFM tips were immersed into the solution. The chamber was covered to 
prevent chloroform evaporation. After 1.5 hours, tips were removed from the solution, 
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washed three times in chloroform, and dried under the stream of nitrogen. The use of PEG 
spacer, as an intermittent link for biomolecule attachment to the cantilever, provides 
important advantages in molecular recognition force spectroscopy [22-26]. The linker is 
chemically and physically inert, allowing rapid and free reorientation of biomolecules. The 
spacing between molecule and the tip reduces the likelihood of molecules being crushed 
during the probe-surface contact. Non-linear elastic properties of PEG make it easy to 
discriminate between the non-specific and specific interaction events. 
Proteins (Laminin, ApoE3, or ApoE4) were immobilized on AFM probes using the 
amine-amine reactive linker aldehyde-PEG-NHS. A sheet of parafilm was pressed into a 
glass petri dish. AFM cantilever chips were set onto the film in a circular “wagon wheel” 
pattern so that the tips were pointed upward and inward. 10 - 30 l of the protein solution was 
applied onto the cantilevers. The proteins were allowed to react for one hour to couple via 
intrinsic amino groups to the aldehyde-function of the PEG linker on the tip.  After one hour, 
5 l of 1M ethanolamine was added to the protein solution drop to inactivate unreacted 
aldehyde groups.  
 
2.3.2 Substrate preparation for AFM experiments 
Substrates for AFM experiments were prepared as follows: 20 l of protein solution, 
i.e. Aβ, ApoE3, ApoE4, or complexes of ApoE3 + Aβ (1:1 molar ratio), and ApoE4 + Aβ 
(1:1 molar ratio). Complexes were left to react at 4°C for 1 hour.  Solutions were added onto 
a freshly cleaved mica (Agar Scientific, UK) substrate which was already inserted into a 
liquid cell. 100 l of dH2O were added to a cell. Proteins were left to adsorb to the substrate 
for 30 min. The mica substrate was washed with water to ensure that only adsorbed proteins 
remained on the substrate.  
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Aβ has a tendency to form large aggregates with time [27]. To maintain the solubility 
state of Aβ, fresh protein was deposited on the mica every 4 hours, and a new functionalized 
AFM tip was used in the experiments. Images of Aβ were captured immediately after 
deposition and before the possible A rearrangement, i.e. after 4 hours. No Aβ agglomeration 
in fibrillar form was observed on the mica during any stage of the experiment. 
 
2.3.3 Single molecule force spectroscopy experiments 
Sample imaging and molecular force spectroscopy experiments were performed in 
water using Agilent 5500 Scanning Probe Microscopy, MAC III, Agilent Technologies, US. 
Images were acquired using the same cantilevers in contact mode. Actual constant values of 
AFM cantilevers were measured in liquid using a built-in thermal noise method [28] before 
each experimental set. Determined force constant was used to calculate actual loading and 
unbinding forces. Force spectroscopy data were acquired at loading rates ranging from 3000 
– 160000 pN/s, corresponding to retraction rates of 0.08 – 3 m/s. At least 1000 curves were 
recorded for each experimental condition. The following tip-substrate pairs were measured: 
Laminin - Aβ, Laminin - ApoE3, Laminin - ApoE4, or Laminin (on the tip), against 
complexes of ApoE3 + Aβ, or ApoE4 + Aβ. In a separate run of experiments, we used 
ApoE3 on the tip and Aβ as a substrate, or ApoE4 on the tip and Aβ as a substrate. All 
experiments were repeated independently three times, allowing 2 – 3 weeks between each 
repeat.  
 
2.3.4 Data Analysis 
PicoView 1.10 and PicoImage (Agilent Technologies, US) software were used for 
data acquisition and image analysis, respectively. Force curves were analysed using PUNIAS 
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macro software (http://punias.voila.net/).  From several hundred single molecule unbinding 
events, the probability density function (PDF) was constructed as described in [29, 30]. The 
PDFs were fitted with the equation: 
      
 
      
     
      
 
   
  
 
          (1) 
where p(F) is the estimate for the PDF that the bond will break at force F, i and i are 
rupture force and accuracy respectively, with the sum running over all N (several hundred in 
our case) rupture events. PDF gives the statistical distribution of rupture forces (termed as 
“unbinding force”). The most probable unbinding force was then determined by fitting Gauss 
function to the estimated PDF using Origin analytical software.  
In a single barrier model [31], the unbinding force FU is given as a function of the loading 
rate: 
   
   
  
      
   
  
       
   
  
        (2) 
where kBT is the thermal energy (4.1 pNnm at room temperature), koff  (1/s) is the dissociation 
rate constant, x is a length scale in nm describing the separation of the receptor-ligand pair 
between the bound and the transition state, r (pN/s) is the loading rate. The parameters x and 
koff were determined by fitting FU against ln(r). 
 
3. Results 
3.1 Immunofluorescence 
Aβ42 was observed in the walls of blood vessels from brains with Alzheimer’s 
disease (Figure 1). ApoE was also observed in the walls of arteries, between the layers of 
smooth muscle cells and co-localized with Aβ42 (Figure 1). 
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3.2 Molecule force spectroscopy 
Force-spectroscopy experiments were performed to study the reciprocal influence of 
different isoforms of ApoE and Aβ on their binding interactions with laminin. The protein 
adsorption on the mica, its conformation and size was investigated by contact-mode AFM 
imaging in liquid. As an example, Figure 2a shows Aβ assemblies on the substrate. 
Scratching away adhered molecules with higher force, gave 2 x 2 m area of bare (or almost 
bare) mica (Figure 2b). This simple experiment further confirmed protein presence on the 
surface. Furthermore, it also indicates that Aβ is in the form of small oligomers (molecules 
were of about 5 ± 0.5 nm in height) instead of fibrils as described in Refs. [32, 33] or large 
agglomerates. ApoEs were measured to be 15 ± 2 nm in height, and complexes of Aβ with 
ApoE3/4 were 20 ± 2 nm.   
To study specific binding of tip-bound protein to mica-bound protein by force 
spectroscopy, the functionalized tip was repeatedly brought into contact with the protein and 
retracted at constant load and velocity. Figure 3a shows an example of typical force-distance 
curve with a single recognition event.  The cycle starts at a point 1 which corresponds to the 
free cantilever, when the tip is far away from the substrate. The probe comes in contact with 
the surface at point 2, and bends further until it reaches point 3. During unloading, the 
cantilever relaxes to reach point 4, which usually corresponds to the point of contact. If there 
is specific interaction between biomolecules, the unloading curve follows the pass through 
steps 5-7. The cantilever begins to deflect in a non-linear fashion. This characteristic 
signature peak results from the stretching of the polymer linker, and identifies specific ligand-
receptor binding. The force increases until enough energy is transferred to break the bond 
(points 6 to 7), where FU indicates an unbinding force in pN. The tip and substrate are 
completely separated at this point. To ensure that the measured unbinding event is specific to 
the ligand-receptor interaction, the force-displacement curves between the functionalized tip 
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and clean mica in an aqueous environment were recorded. As expected, all loading and 
unloading curves were identical in control experiments, Figure 3b.  
Force-displacement cycles were analysed as described in materials and methods. The 
most probable unbinding force and binding probabilities (BP) were calculated using 
Equations 1 and 2. The FU and binding probability results for various ligand-receptor pairs 
recorded at 1 Hz with 100-300 nm amplitude, resulting in loading rates from 15,000 – 70,000 
pN/s, are presented in Figure 4. The unbinding forces between laminin and ApoE3 and 
between laminin and apoE4 are the same (450 ± 50 pN), Figure 4a. However, when Aβ was 
added to ApoE, less energy was required to detach a laminin molecule from any of the 
complexes (~ 270 ± 25 pN). It was also noted that unbinding of ApoE3 and ApoE4 from Aβ 
occurred with similar force of ~ 270 ± 25 pN, while laminin bonded to Aβ at forces of 350 ± 
35 pN.  
The binding probability was defined as the probability of recording an unbinding 
event in a force-distance cycle in relation to all recorded cycles, i.e. how many curves with 
specific recognition were recorded out of 1000 measured cycles. Results of binding 
probability for various tip-substrate interaction are given in Figure 4b, where BP of 1 would 
correspond to 100%, 0.3 = 30%, and so on. Laminin tended to bind more frequently to 
ApoE3, Aβ, and Aβ+ApoE3 complex with a probability of ~ 30 ± 3%. BP of laminin to 
ApoE4 was calculated to be 15 ± 1.5 %, and for Aβ+ApoE4 complex it was 22 ± 2 %. Very 
few binding events were recorded between ApoE3/4 (tip) and Aβ (substrate), where 7% of all 
specific recognition curves were recorded for ApoE4 - Aβ interaction, and 2% for ApoE4 - 
Aβ (Figure 4b, grey columns). Aβ was always immobilized on the mica, and so the protein 
orientation might have been such that binding sites were directed towards the substrate 
leaving very few sites exposed. In this case, ApoEs attached to the AFM tip would hardly 
bind to Aβ. If this were the case, similar results should be observed between laminin (tip) and 
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Aβ (substrate). But experimental binding probability between laminin and Aβ was 30%, and 
so this would indicate that ApoEs do not interact with Aβ so avidly.   
 
3.3 Kinetic constants and affinities 
The parameters of prime interest in describing any biological ligand-receptor system 
are the rates of spontaneous association (or on-rate, kon), dissociation (off-rate, koff), and their 
ratio the dissociation constant (also known as affinity) KD = koff/kon which describes the 
equilibrium behaviour. To calculate association and dissociation constants, molecular force 
spectroscopy experiments were carried out in a range of loading rates from 3000 – 160000 
pN/s, and tip-substrate contact times 0.001 – 0.5 s. To estimate kinetic on-rate constant, kon, 
from single molecule unbinding force measurements, it is necessary to determine interaction 
time  (the time required for half maximal recognition probability) and effective 
concentration ceff, for kon = ( ceff)
-1
[23, 34, 35]. The effective concentration is described as a 
number of binding receptor molecules within the effective volume accessible for free 
equilibrium interaction, and is explained in detail elsewhere [23, 34, 35]. The interaction time 
was calculated from the binding probability at different encounter times by fitting P = A(1 – 
exp( – (t – t0)/)) (where t0 is a lag time, A is the maximum observable  binding probability) 
[34]. An example is shown in figure Figure 5(a) for ApoE4 interaction with Aβ.  
Furthermore, according to single barrier theory, the unbinding force rises linearly with 
respect to logarithmically increasing loading rate [30, 36, 37]. A linear increase of the most 
probable unbinding force versus loading rate was observed for all measured interactions. As 
an example, Figure 5(b) demonstrates unbinding force dependence on loading rate for ApoE4 
interaction with Aβ. The off-rate is determined from the linear fit extrapolated at zero force 
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[36, 37]. The slope of the fit corresponds to kT/x in Equation 2. The intercept at zero force 
allows the calculation of koff from Equation 2,   
   
  
       
   
  
  . 
Calculated rate constants and affinities for all AFM measured ligand-receptor pairs is 
given in Table 1. The results for all AFM measurements demonstrate that Aβ + ApoE3 
complex has a stronger binding to laminin than Aβ + ApoE4. 
 
4. Discussion 
The results of the present study have shown that ApoE and Aβ42 co-localize within 
basement membranes of the cerebral vasculature that form the elimination pathways for Aβ 
from the brain, consistent with Aβ being eliminated from the brain as a complex with ApoE 
[12]. Electron paramagnetic resonance spectroscopy study of the interactions between 
apolipoprotein E and oligomers of Aβ40 demonstrate that ApoE3 has a higher affinity for 
Aβ40 compared to ApoE4 [38]. Our own data show stronger binding of Aβ40 to ApoE4 
compared with ApoE3. Other studies have shown that ApoE4 binds Aβ with higher affinity 
compared with ApoE3 and this is reversed when using lipidated forms of ApoE [39, 40] . 
More recently, using HEK-293 cells expressing ApoE3 or ApoE4 and Aβ42 it was shown 
that the interactions between ApoE4 and Aβ42 are weaker compared with ApoE3- Aβ42, 
with ApoE3-Aβ complexes saturable and dependent on Aβ concentrations [41]. We did not 
use Aβ42 in this study, but Aβ40, the type predominantly found in the walls of blood vessels 
and we used a ratio of Aβ-ApoE of 1:1, as our aim was to concentrate on the interaction of 
the Aβ40-ApoE3/4 complexes with the laminin component of the basement membranes.   
We found that the complex Aβ + ApoE4 interacted with laminin less avidly (KD = 
1.52 x 10
-7
 M
-1) compared to the complex Aβ + ApoE3 (KD = 1.46 x 10
-8
 M
-1
). These results, 
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together with our mathematical modelling studies (4), suggest that the perivascular clearance 
of soluble Aβ along cerebrovascular basement membranes may be slower in ApoE4 carriers, 
compared to ApoE3 carriers, due to a lack of biophysical interaction between Aβ and 
individual components of basement membranes (in this case laminin). Less efficient 
biophysical interaction between Aβ + ApoE4 and basement membrane proteins, such as 
laminin would mean that there would be weaker attachment to the basement membrane 
during passage of the pulse wave and ApoE4-Aβ complexes may remain in the extracellular 
spaces as seeds for plaques, promoting inflammation [42, 43]. Thus Aβ + ApoE4 would not 
be driven out of the brain along perivascular pathways as efficiently as Aβ + ApoE3. This 
may be an important factor in the failure of elimination of Aβ from the brain in ApoE4 
carriers and the consequent accumulation of Aβ in the brain and artery walls and the 
development of Alzheimer's disease. Apolipoprotein E appears to be located in the 
perivascular compartment of blood vessels in the human brain and co-localizes with Aβ in 
Alzheimer’s disease [44]. 
Elimination of Aβ from the brain in Alzheimer's disease has been the major objective 
of a number of Aβ immunotherapy trials. Although in many patients insoluble plaques of Aβ 
are cleared from cortical areas, an increase in the severity of CAA has been reported [45].  
This suggests that Aβ cleared from the brain parenchyma becomes entrapped in the 
perivascular drainage pathways with the ultimate failure of elimination of Aβ from the brain 
[45]. Recently it has also been demonstrated that Aβ immunotherapy was associated with 
redistribution of ApoE from cortical plaques to cerebral vessel walls, mirroring the altered 
distribution of Aβ 42 from the plaques towards the walls of blood vessels [46], consistent 
with ApoE/Aβ travelling as a complex. Complications are associated with Aβ 
immunotherapy, designated Amyloid Related Imaging Abnormalities (ARIA) [47].  Evidence 
suggests that ARIAs are due to vascular alterations, including increased severity of CAA. As 
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ARIAs occur more frequently in AD patients who are APOE ε4 carriers than non-ε4 carriers, 
the differential binding of Aβ/apoE E3 and E4 to laminin demonstrated in this study may be 
relevant to the causation of ARIA as Aβ is being removed from the brain.  
 
5. Conclusions 
The results of this study add to our knowledge of the dynamics of perivascular 
drainage and its importance for the elimination of Aβ from the brain. Accumulation of 
soluble and insoluble Aβ in brain parenchyma and in artery walls occurs with advancing age 
and is enhanced in those possessing the ApoE4 allele. Experimental and theoretical data 
indicate that vascular pulsations are the driving force for perivascular elimination of Aβ with 
the contrary (reflection) wave driving Aβ and other solutes out of the brain in the reverse 
direction to blood flow [11]. Reduction in the amplitude of the pulse wave may occur as 
arteries stiffen with age and arteriosclerosis, thus reducing the motive force for the 
perivascular drainage of Aβ and other solutes from the brain. 
The present study suggests that the presence of ApoE4 further reduces the efficiency 
of perivascular elimination of Aβ due to reduced attachment of ApoE4/Aβ complexes to 
basement membranes in the drainage pathway, although the type of Aβ and the lipidation 
status of ApoE are crucial [12]. Such reduced attachment may allow oscillation of Aβ within 
the basement membrane during passage of the pulse wave and thus impair the progress of Aβ 
out of the brain along the perivascular pathways. 
Therapeutic strategies that optimise attachment of soluble metabolites to basement 
membrane proteins may also optimise elimination of those metabolites from the brain. The 
present study has established a principle that could be developed in the future to test therapies 
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for the prevention of Alzheimer's disease, based on manipulating the Aβ-ApoE interactions 
with basement membrane proteins. 
 
Acknowledgements 
We are grateful to Cheryl Hawkes for technical help, to the Engineering and Physical 
Sciences Research Council of UK and Alzheimer’s Research UK for providing the funding 
for this study, to the South West Dementia Brain Bank for the brain tissue.   
 
References 
[1] D.R. Thal, W.S.T. Griffin, R.A.I. de Vos, E. Ghebremedhin, Cerebral amyloid angiopathy 
and its relationship to Alzheimer's disease, Acta Neuropathol, 115 (2008) 599-609. 
[2] D.R. Thal, A. Papassotiropoulos, T.C. Saido, W.S.T. Griffin, R.E. Mrak, H. Kolsch, K. 
Del Tredici, J. Attems, E. Ghebremedhin, Capillary cerebral amyloid angiopathy identifies a 
distinct APOE epsilon 4-associated subtype of sporadic Alzheimer's disease, Acta 
Neuropathol, 120 (2010) 169-183. 
[3] R.O. Carare, C.A. Hawkes, M. Jeffrey, R.N. Kalaria, R.O. Weller, Review: Cerebral 
amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination 
failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy, Neuropath 
Appl Neuro, 39 (2013) 593-611. 
[4] R. Deane, A. Sagare, K. Hamm, M. Parisi, S. Lane, M.B. Finn, D.M. Holtzman, B.V. 
Zlokovic, apoE isoform-specific disruption of amyloid beta peptide clearance from mouse 
brain, J Clin Invest, 118 (2008) 4002-4013. 
[5] R.O. Weller, M. Subash, S.D. Preston, I. Mazanti, R.O. Carare, Perivascular drainage of 
amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and 
Alzheimer's disease, Brain Pathol, 18 (2008) 253-266. 
[6] I. Szentistvanyi, C.S. Patlak, R.A. Ellis, H.F. Cserr, Drainage of Interstitial Fluid from 
Different Regions of Rat-Brain, Am J Physiol, 246 (1984) F835-F844. 
[7] R.O. Carare, M. Bernardes-Silva, T.A. Newman, A.M. Page, J.A.R. Nicoll, V.H. Perry, 
R.O. Weller, Solutes, but not cells, drain from the brain parenchyma along basement 
membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and 
neuroimmunology, Neuropath Appl Neuro, 34 (2008) 131-144. 
[8] Y. Shinkai, M. Yoshimura, Y. Ito, A. Odaka, N. Suzuki, K. Yanagisawa, Y. Ihara, 
Amyloid P-Proteins-1-40 and P-Proteins-1-42(43) in the Soluble Fraction of Extracranial and 
Intracranial Blood-Vessels, Ann Neurol, 38 (1995) 421-428. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
 
[9] C.A. Hawkes, W. Hartig, J. Kacza, R. Schliebs, R.O. Weller, J.A. Nicoll, R.O. Carare, 
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of 
cerebral amyloid angiopathy, Acta Neuropathol, 121 (2011) 431-443. 
[10] C.A. Hawkes, P.M. Sullivan, S. Hands, R.O. Weller, J.A.R. Nicoll, R.O. Carare, 
Disruption of Arterial Perivascular Drainage of Amyloid-beta from the Brains of Mice 
Expressing the Human APOE epsilon 4 Allele, Plos One, 7 (2012). 
[11] D. Schley, R. Carare-Nnadi, C.P. Please, V.H. Perry, R.O. Weller, Mechanisms to 
explain the reverse perivascular transport of solutes out of the brain, J Theor Biol, 238 (2006) 
962-974. 
[12] L.M. Tai, S. Mehra, V. Shete, S. Estus, G.W. Rebeck, G.J. Bu, M.J. LaDu, Soluble 
apoE/A beta complex: mechanism and therapeutic target for APOE4-induced AD risk, Mol 
Neurodegener, 9 (2014). 
[13] S.R. Li, K. Oka, D. Galton, J. Stocks, Bst-1 Rflp at the Human Lipoprotein-Lipase (Lpl) 
Gene Locus, Nucleic Acids Res, 16 (1988) 11856-11856. 
[14] S.R. Li, K. Oka, D. Galton, J. Stocks, Pvu-Ii Rflp at the Human Lipoprotein-Lipase (Lpl) 
Gene Locus, Nucleic Acids Res, 16 (1988) 2358-2358. 
[15] D.R. Riddell, H. Zhou, K. Atchison, H.K. Warwick, P.J. Atkinson, J. Jefferson, L. Xu, S. 
Aschmies, Y. Kirksey, Y. Hu, E. Wagner, A. Parratt, J. Xu, Z.T. Li, M.M. Zaleska, J.S. 
Jacobsen, M.N. Pangalos, P.H. Reinhart, Impact of Apolipoprotein E (ApoE) Polymorphism 
on Brain ApoE Levels, J Neurosci, 28 (2008) 11445-11453. 
[16] P.B. Verghese, J.M. Castellano, K. Garai, Y.N. Wang, H. Jiang, A. Shah, G.J. Bu, C. 
Frieden, D.M. Holtzman, ApoE influences amyloid-beta (A beta) clearance despite minimal 
apoE/A beta association in physiological conditions, P Natl Acad Sci USA, 110 (2013) 
E1807-E1816. 
[17] M.C. Herzig, W.E. Van Nostrand, M. Jucker, Mechanism of cerebral beta-amyloid 
angiopathy: Murine and cellular models, Brain Pathol, 16 (2006) 40-54. 
[18] J. Nicoll, The effects of A beta immunization on the pathology of Alzheimer disease, 
Neurobiol Aging, 27 (2006) S15-S15. 
[19] J.A.R. Nicoll, E. Barton, D. Boche, J.W. Neal, I. Ferrer, P. Thompson, C. Vlachouli, D. 
Wilkinson, A. Bayer, D. Games, P. Seubert, D. Schenk, C. Holmes, A beta species removal 
after A beta(42) immunization, J Neuropath Exp Neur, 65 (2006) 1040-1048. 
[20] C.K. Riener, C.M. Stroh, A. Ebner, C. Klampfl, A.A. Gall, C. Romanin, Y.L. 
Lyubchenko, P. Hinterdorfer, H.J. Gruber, Simple test system for single molecule recognition 
force microscopy, Analytica Chimica Acta, 479 (2003) 59-75. 
User's Guide in, Agilent technologies, Inc., 2010. 
[22] A. Ebner, P. Hinterdorfer, H.J. Gruber, Comparison of different aminofunctionalization 
strategies for attachment of single antibodies to AFM cantilevers, Ultramicroscopy, 107 
(2007) 922-927. 
[23] P. Hinterdorfer, W. Baumgartner, H.J. Gruber, K. Schilcher, H. Schindler, Detection and 
localization of individual antibody-antigen recognition events by atomic force microscopy, 
Proceedings of the National Academy of Sciences of the United States of America, 93 (1996) 
3477-3481. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
[24] V.J. Morris, Kirby, A.R., Gunning, A.P., Force spectroscopy, in:  Atomic Force 
Microscopy for Biologist, Imperila College Press, 2010, pp. 356-396. 
[25] G.S. Watson, Watson, J.A., Quantitative measurements of nano forces using Atomic 
Force Microscopy, VDM Verlag Dr. Muelller, 2008. 
[26] W.F. Heinz, J.H. Hoh, Spatially resolved force spectroscopy of biological surfaces using 
the atomic force microscope, Trends in Biotechnology, 17 (1999) 143-150. 
[27] D.R. Thal, M. Fandrich, Protein aggregation in Alzheimer's disease: A beta and tau and 
their potential roles in the pathogenesis of AD, Acta Neuropathol, 129 (2015) 163-165. 
[28] J.L. Hutter, J. Bechhoefer, Calibration of Atomic-Force Microscope Tips, Review of 
Scientific Instruments, 64 (1993) 1868-1873. 
[29] W. Baumgartner, P. Hinterdorfer, H. Schindler, Data analysis of interaction forces 
measured with the atomic force microscope, Ultramicroscopy, 82 (2000) 85-95. 
[30] C. Rankl, F. Kienberger, H. Gruber, D. Blaas, P. Hinterdorfer, Accuracy estimation in 
force spectroscopy experiments, Japanese Journal of Applied Physics Part 1-Regular Papers 
Brief Communications & Review Papers, 46 (2007) 5536-5539. 
[31] E. Evans, K. Ritchie, Dynamic strength of molecular adhesion bonds, Biophysical 
Journal, 72 (1997) 1541-1555. 
[32] L.M. Jungbauer, C. Yu, K.J. Laxton, .J. Ladu, Preparation of fluorescently-labeled 
amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and 
function, J Mol Recognit, 22 (2009) 403-413. 
[33] J.D. Harper, S.S. Wong, C.M. Lieber, P.T. Lansbury, Assembly of A beta amyloid 
protofibrils: An in vitro model for a possible early event in Alzheimer's disease, 
Biochemistry, 38 (1999) 8972-8980. 
[34] C. Rankl, F. Kienberger, L. Wildling, J. Wruss, H.J. Gruber, D. Blaas, P. Hinterdorfer, 
Multiple receptors involved in human rhinovirus attachment to live cells, Proceedings of the 
National Academy of Sciences of the United States of America, 105 (2008) 17778-17783. 
[35] W. Baumgartner, Gruber, H.J., Hinterdorfer, P., Drenckhahn, D., Affinity of trans-
interacting VE-candherin determined by atomic force microscopy, Single Molecules, 1 
(2000) 119-122. 
[36] F. Schwesinger, R. Ros, T. Strunz, D. Anselmetti, H.J. Guntherodt, A. Honegger, L. 
Jermutus, L. Tiefenauer, A. Pluckthun, Unbinding forces of single antibody-antigen 
complexes correlate with their thermal dissociation rates, Proceedings of the National 
Academy of Sciences of the United States of America, 97 (2000) 9972-9977. 
[37] T. Strunz, K. Oroszlan, R. Schafer, H.J. Guntherodt, Dynamic force spectroscopy of 
single DNA molecules, Proceedings of the National Academy of Sciences of the United 
States of America, 96 (1999) 11277-11282. 
[38] J. Petrlova, H.S. Hong, D.A. Bricarello, G. Harishchandra, G.A. Lorigan, L.W. Jin, J.C. 
Voss, A differential association of Apolipoprotein E isoforms with the amyloid-beta oligomer 
in solution, Proteins, 79 (2011) 402-416. 
[39] M.J. Ladu, M.T. Falduto, A.M. Manelli, C.A. Reardon, G.S. Getz, D.E. Frail, Isoform-
Specific Binding of Apolipoprotein-E to Beta-Amyloid, J Biol Chem, 269 (1994) 23403-
23406. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
[40] M.J. Ladu, T.M. Pederson, D.E. Frail, C.A. Reardon, G.S. Getz, M.T. Falduto, 
Purification of Apolipoprotein-E Attenuates Isoform-Specific Binding to Beta-Amyloid, J 
Biol Chem, 270 (1995) 9039-9042. 
[41] L.M. Tai, T. Bilousova, L. Jungbauer, S.K. Roeske, K.L. Youmans, C.J. Yu, W.W. 
Poon, L.B. Cornwell, C.A. Miller, H.V. Vinters, L.J. Van Eldik, D.W. Fardo, S. Estus, G.J. 
Bu, K.H. Gylys, M.J. LaDu, Levels of Soluble Apolipoprotein E/Amyloid-beta (A beta) 
Complex Are Reduced and Oligomeric A beta Increased with APOE4 and Alzheimer Disease 
in a Transgenic Mouse Model and Human Samples, J Biol Chem, 288 (2013) 5914-5926. 
[42] G.A. Rodriguez, L.M. Tai, M.J. LaDu, G.W. Rebeck, Human APOE4 increases 
microglia reactivity at A beta plaques in a mouse model of A beta deposition, J 
Neuroinflamm, 11 (2014). 
[43] L.M. Tai, S. Ghura, K.P. Koster, V. Liakaite, M. Maienschein-Cline, P. Kanabar, N. 
Collins, M. Ben-Aissa, A.Z. Lei, N. Bahroos, S.J. Green, B. Hendrickson, L.J. Van Eldik, 
M.J. LaDu, APOE-modulated A beta-induced neuroinflammation in Alzheimer's disease: 
current landscape, novel data, and future perspective, J Neurochem, 133 (2015) 465-488. 
[44] S. Utter, I.Y. Tamboli, J. Walter, A.R. Upadhaya, G. Birkenmeier, C.U. Pietrzik, E. 
Ghebremedhin, D.R. Thal, Cerebral small vessel disease-induced apolipoprotein E leakage is 
associated with Alzheimer disease and the accumulation of amyloid beta-protein in 
perivascular astrocytes, J Neuropath Exp Neur, 67 (2008) 842-856. 
[45] D. Boche, C. Holmes, D. Wilkinson, V. Hopkins, A. Bayer, R. Jones, R. Bullock, S. 
Love, J. Neal, G. Yadegarfar, E. Zotova, J.A.R. Nicoll, Continued progression of 
neurodegeneration in Alzheimer's disease despite complete removal of the A beta plaques?, 
Neuropath Appl Neuro, 34 (2008) 1-1. 
[46] K. Sakai, D. Boche, R. Carare, D. Johnston, C. Holmes, S. Love, J.A.R. Nicoll, A beta 
immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy, Acta 
Neuropathol, 128 (2014) 777-789. 
[47] D.J. Werring, R. Sperling, Inflammatory cerebral amyloid angiopathy and amyloid-
modifying therapies: Variations on the Same ARIA?, Ann Neurol, 73 (2013) 439-441. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
Figure Captions 
 
Figure 1.  Triple immunostaining for Amyloid-β (Aβ) 1-42 (red), pan-Apolipoprotein E 
(ApoE) (blue), smooth muscle actin (green) of a leptomeningeal artery of a case of 
Alzheimer’s disease. Aβ42 colocalizes with apolipoprotein E (magenta) adjacent to smooth 
muscle actin, suggesting that Aβ and ApoE colocalize in the basement membranes of the 
smooth muscle tunica media. Confocal Leica SP5 image, a 63 objective was used, scale bar 
10 m. 
Figure 2. Contact-mode AFM images in liquid of A deposited on mica (a). The presence of 
protein molecules was proved by scratching the proteins with higher force in an area of 2 x 2 
m (b). Scale bar – 500 nm  
Figure 3. Example of force-displacement curves obtained during single molecule force 
spectroscopy experiments for an experimental set tip - ApoE3, substrate - A. (a) Typical 
force-displacement cycle with a single specific interaction. See text for explanation. (b) 
Control - no interaction between biomolecules attached to the tip and clean mica substrate.  
Figure 4. (a) Most probable unbinding force, FU, and (b) specific binding probability for 
various tip-substrate pairs. Results are given for force-displacement cycles obtained at 1 Hz 
with 100 – 300 nm amplitude. 
Figure 5. Kinetics of ligand-receptor binding. (a) Binding probability as a function of contact 
time. Solid line is the result of least- squares fit. (b) Unbinding force as a function of loading 
rate. 
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Table 1. Association (kon) and dissociation (koff) rates, and affinity (KD) obtained by AFM. 
The lower KD value indicates stronger interaction. Aβ + ApoE3 has a stronger binding to 
laminin, compared to Aβ + ApoE4. 
 
 
Table 1. 
Tip Substrate kon (1/Ms) koff (1/s) KD (1/M) 
ApoE3 A 2.26 x10
4
 0.01091 4.83 x10
-7
 
ApoE4 A 1.08 x10
5
 0.01025 9.45 x10
-8
 
Laminin A 1.10 x10
6
 0.01241 1.13 x10
-8
 
ApoE3 2.08 x10
6
 0.00541 2.60 x10
-9
 
ApoE4 1.07 x10
6
 0.00527 4.94 x10
-9
 
A + ApoE3 1.23 x10
6
 0.018 1.46 x10
-8
 
A + ApoE4 1.46 x10
5
 0.02224 1.52 x10
-7
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Highlights  
 
1. Atomic force microscopy measures binding affinity between proteins. 
2. The affinity of ApoE4/Aβ complexes to laminin is weaker than ApoE3/Aβ to laminin. 
3. Perivascular clearance of Aβ + ApoE4 is less efficient compared to Aβ + ApoE3. 
